HAVERHILL — A petition with nearly 1,200 signatures from concerned residents and property owners is calling to stop a proposed 24-bed men’s substance use and mental health facility from moving into the neighborhood.
The petition, posted on Change.org and titled “Stop Riverbend House from coming into our neighborhood,” urges Haverhill residents to oppose Riverbend’s plan to open the “Bradford House” at 11 Kingsbury Ave.
This page requires Javascript.
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
SALEM — A group of about 30 community members walked from the Salem Common to Riley Plaza on Thursday as a part of the annual Walk for Overdose Awareness.
The event included speakers stressing the importance of creating a larger support network for community members struggling with substance abuse and addiction.
This page requires Javascript.
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Workers who are injured on the job are at higher risk for fatal opioid-related overdoses, according to a new study, which calls for renewed efforts to reduce the stigma of drug addiction.
The report, released Thursday by the state Department of Public Health, found that working-age Massachusetts residents who died between 2011 and 2020 were 35% more likely to have died of an opioid-related overdose if they had previously been injured at work.
DPH researchers compiled information about individuals’ employment and work-related injury status from their workers’ compensation claims and linked it with data from their death certificates.
Researchers reviewed the details of 4,304 working-age adults who died between 2011 and 2020 and found at least 17.2% had at least one workplace injury claim and died of an opioid-related overdose, according to the study.
Public health officials say the study is the first linking the impact of work-related injuries to opioid-related overdose deaths.
“Occupational injuries can take both a physical and mental toll, and those who suffer injuries at work may be discouraged from seeking help because of stigmatization and fear of losing their jobs,” Health and Human Services Secretary Kate Walsh said in a prepared statement. “Avoiding or delaying care can lead to a preventable overdose death.”
She called for stepped-up efforts to “eliminate the stigma that accompanies substance use disorder in all sectors of society, including the workplace.”
The release of the report comes as opioid overdose deaths remain devastatingly high in the Bay State, despite a slight decrease over the past year.
There were 2,323 confirmed or suspected opioid-related deaths in Massachusetts from Oct. 1, 2022 to Sept. 30, 2023 — eight fewer than the same period in 2021, according to a report released in December by the health department.
Health officials attributed the persistently high death rates to the effects of an “increasingly poisoned drug supply,” primarily with the powerful synthetic opioid fentanyl.
Fentanyl was present in 93% of the overdose deaths where a toxicology report was available, state officials noted.
Curbing opioid addiction has been a major focus on Beacon Hill for a number of years with hundreds of millions of dollars being devoted to expanding treatment and prevention efforts.
The state has set some of the strictest opioid prescribing laws in the nation, including a cap on new prescriptions in a seven-day period and a requirement that doctors consult a state prescription monitoring database before prescribing an addictive opioid.
The Opioid Recovery and Remediation Fund, created by the state Legislature in 2020, has received more than $101 million from settlements with drug makers and distributors over their alleged role in the opioid crisis, according to the Executive Office of Health and Human Services.
More than 25,000 people have died from opioid-related overdoses in Massachusetts since 2011, according to state records.
Nationally, fatal drug overdoses fell by roughly 3% in 2023, according data from the U.S. Centers for Disease Control and Prevention.
But the toll from fatal overdoses in 2023 remained high, claiming 107,543 lives, the federal agency said.
Fentanyl and other synthetic opioids were responsible for about 70% of lives lost, while methamphetamine and other synthetic stimulants are responsible for about 30% of deaths, the CDC said.
“The shift from plant-based drugs, like heroin and cocaine, to synthetic, chemical-based drugs, like fentanyl and methamphetamine, has resulted in the most dangerous and deadly drug crisis the United States has ever faced,” Anne Milgram, head of the Drug Enforcement Administration, said in a recent statement.
The DEA points to Mexican drug cartels, who it says are smuggling large quantities of fentanyl and other synthetic drugs manufactured in China into the country, along the southern border.
“The suppliers, manufacturers, distributors, and money launderers all play a role in the web of deliberate and calculated treachery orchestrated by these cartels,” she said.
Workers who are injured on the job are at higher risk for fatal opioid-related overdoses, according to a new study, which calls for renewed efforts to reduce the stigma of drug addiction.
The report, released Thursday by the state Department of Public Health, found that working-age Massachusetts residents who died between 2011 and 2020 were 35% more likely to have died of an opioid-related overdose if they had previously been injured at work.
DPH researchers compiled information about individuals’ employment and work-related injury status from their workers’ compensation claims and linked it to data from their death certificates.
Researchers reviewed the details of 4,304 working-age adults who died between 2011 and 2020 and found at least 17.2% had at least one workplace injury claim and died of an opioid-related overdose, according to the study.
Public health officials say the study is the first linking the impact of work-related injuries to opioid-related overdose deaths.
“Occupational injuries can take both a physical and mental toll, and those who suffer injuries at work may be discouraged from seeking help because of stigmatization and fear of losing their jobs,” Health and Human Services Secretary Kate Walsh said in a statement. “Avoiding or delaying care can lead to a preventable overdose death.”
Walsh called for stepped-up efforts to “eliminate the stigma that accompanies substance use disorder in all sectors of society, including the workplace.”
The release of the report comes as opioid overdose deaths remain devastatingly high in the Bay State, despite a slight decrease over the past year.
There were 2,323 confirmed or suspected opioid-related deaths in Massachusetts from Oct. 1, 2022, to Sept. 30, 2023 — eight fewer than the same period in 2021, according to a report released in December by the health department.
Health officials attributed the persistently high death rates to the effects of an “increasingly poisoned drug supply,” primarily with the powerful synthetic opioid fentanyl.
Fentanyl was present in 93% of the overdose deaths where a toxicology report was available, state officials noted.
Curbing opioid addiction has been a major focus on Beacon Hill for a number of years with hundreds of millions of dollars being devoted to expanding treatment and prevention efforts.
The state has set some of the strictest opioid-prescribing laws in the nation, including a cap on new prescriptions in a seven-day period and a requirement that doctors consult a state prescription monitoring database before prescribing an addictive opioid.
The Opioid Recovery and Remediation Fund, created by the state Legislature in 2020, has received more than $101 million from settlements with drug makers and distributors over their alleged role in the opioid crisis, according to the Executive Office of Health and Human Services.
More than 25,000 people have died from opioid-related overdoses in Massachusetts since 2011, according to state records.
Nationally, fatal drug overdoses fell by roughly 3% in 2023, according data from the U.S. Centers for Disease Control and Prevention.
But the toll from fatal overdoses in 2023 remained high, claiming 107,543 lives, the federal agency said.
Fentanyl and other synthetic opioids were responsible for approximately 70% of lives lost, while methamphetamine and other synthetic stimulants are responsible for approximately 30% of deaths, the CDC said.
“The shift from plant-based drugs, like heroin and cocaine, to synthetic, chemical-based drugs, like fentanyl and methamphetamine, has resulted in the most dangerous and deadly drug crisis the United States has ever faced,” Anne Milgram, head of the Drug Enforcement Administration, said in a recent statement.
The DEA points to Mexican drug cartels, who it says are smuggling large quantities of fentanyl and other synthetic drugs manufactured in China into the country along the southern border.
“The suppliers, manufacturers, distributors, and money launderers all play a role in the web of deliberate and calculated treachery orchestrated by these cartels,” she said.
Christian M. Wade covers the Massachusetts Statehouse for North of Boston Media Group’s newspapers and websites. Email him at cwade@cnhinews.com.
This article was featured in One Story to Read Today, a newsletter in which our editors recommend a single must-read from The Atlantic, Monday through Friday. Sign up for it here.
Three years ago, while the nation’s attention was on the 2020 presidential election, voters in Oregon took a dramatic step back from America’s long-running War on Drugs. By a 17-point margin, Oregonians approved Ballot Measure 110, which eliminated criminal penalties for possessing small amounts of any drug, including cocaine, heroin, and methamphetamine. When the policy went into effect early the next year, it lifted the fear of prosecution for the state’s drug users and launched Oregon on an experiment to determine whether a long-sought goal of the drug-policy reform movement—decriminalization—could help solve America’s drug problems.
Early results of this reform effort, the first of its kind in any state, are now coming into view, and so far, they are not encouraging. State leaders have acknowledged faults with the policy’s implementation and enforcement measures. And Oregon’s drug problems have not improved. Last year, the state experienced one of the sharpest rises in overdose deaths in the nation and had one of the highest percentages of adults with a substance-use disorder. During one two-week period last month, three children under the age of 4 overdosed in Portland after ingesting fentanyl.
For decades, drug policy in America centered on using law enforcement to target people who sold, possessed, or used drugs—an approach long supported by both Democratic and Republican politicians. Only in recent years, amid an epidemic of opioid overdoses and a national reconsideration of racial inequities in the criminal-justice system, has the drug-policy status quo begun to break down, as a coalition of health workers, criminal-justice-reform advocates, and drug-user activists have lobbied for a more compassionate and nuanced response. The new approach emphasizes reducing overdoses, stopping the spread of infectious disease, and providing drug users with the resources they need—counseling, housing, transportation—to stabilize their lives and gain control over their drug use.
Oregon’s Measure 110 was viewed as an opportunity to prove that activists’ most groundbreaking idea—sharply reducing the role of law enforcement in the government’s response to drugs—could work. The measure also earmarked hundreds of millions of dollars in cannabis tax revenue for building a statewide treatment network that advocates promised would do what police and prosecutors couldn’t: help drug users stop or reduce their drug use and become healthy, engaged members of their communities. The day after the measure passed, Kassandra Frederique, executive director of the Drug Policy Alliance, one of the nation’s most prominent drug-policy reform organizations, issued a statement calling the vote a “historic, paradigm-shifting win” and predicting that Oregon would become “a model and starting point for states across the country to decriminalize drug use.”
But three years later, with rising overdoses and delays in treatment funding, even some of the measure’s supporters now believe that the policy needs to be changed. In a nonpartisan statewide poll earlier this year, more than 60 percent of respondents blamed Measure 110 for making drug addiction, homelessness, and crime worse. A majority, including a majority of Democrats, said they supported bringing back criminal penalties for drug possession. This year’s legislative session, which ended in late June, saw at least a dozen Measure 110–related proposals from Democrats and Republicans alike, ranging from technical fixes to full restoration of criminal penalties for drug possession. Two significant changes—tighter restrictions on fentanyl and more state oversight of how Measure 110 funding is distributed—passed with bipartisan support.
Few people consider Measure 110 “a success out of the gate,” Tony Morse, the policy and advocacy director for Oregon Recovers, told me. The organization, which promotes policy solutions to the state’s addiction crisis, initially opposed Measure 110; now it supports funding the policy, though it also wants more state money for in-patient treatment and detox services. As Morse put it, “If you take away the criminal-justice system as a pathway that gets people into treatment, you need to think about what is going to replace it.”
Many advocates say the new policy simply needs more time to prove itself, even if they also acknowledge that parts of the ballot measure had flaws; advocates worked closely with lawmakers on the oversight bill that passed last month. “We’re building the plane as we fly it,” Haven Wheelock, a program supervisor at a homeless-services provider in Portland who helped put Measure 110 on the ballot, told me. “We tried the War on Drugs for 50 years, and it didn’t work … It hurts my heart every time someone says we need to repeal this before we even give it a chance.”
Workers from the organization Central City Concern hand out Narcan in Portland, Oregon, on April 5. (Jordan Gale)
Measure 110 went into effect at a time of dramatic change in U.S. drug policy. Departing from precedent, the Biden administration has endorsed and increased federal funding for a public-health strategy called harm reduction; rather than pushing for abstinence, harm reduction emphasizes keeping drug users safe—for instance, through the distribution of clean syringes and overdose-reversal medications. The term harm reduction appeared five times in the ballot text of Measure 110, which forbids funding recipients from “mandating abstinence.”
Matt Sutton, the director of external relations for the Drug Policy Alliance, which helped write Measure 110 and spent more than $5 million to pass it, told me that reform advocates viewed the measure as the start of a nationwide decriminalization push. The effort started in Oregon because the state had been an early adopter of marijuana legalization and is considered a drug-policy-reform leader. Success would mean showing the rest of the country that “people did think we should invest in a public-health approach instead of criminalization,” Sutton said.
To achieve this goal, Measure 110 enacted two major changes to Oregon’s drug laws. First, minor drug possession was downgraded from a misdemeanor to a violation, similar to a traffic ticket. Under the new law, users caught with up to 1 gram of heroin or methamphetamine, or up to 40 oxycodone pills, are charged a $100 fine, which can be waived if they call a treatment-referral hotline. (Selling, trafficking, and possessing large amounts of drugs remain criminal offenses in Oregon.) Second, the law set aside a portion of state cannabis tax revenue every two years to fund a statewide network of harm-reduction and other services. A grant-making panel was created to oversee the funding process. At least six members of the panel were required to be directly involved in providing services to drug users; at least two had to be active or former drug users themselves; and three were to be “members of communities that have been disproportionately impacted” by drug criminalization, according to the ballot measure.
Backers of Measure 110 said the law was modeled on drug policies in Portugal, where personal drug possession was decriminalized two decades ago. But Oregon’s enforcement-and-treatment-referral system differs from Portugal’s. Users caught with drugs in Portugal are referred to a civil commission that evaluates their drug use and recommends treatment if needed, with civil sanctions for noncompliance. Portugal’s state-run health system also funds a nationwide network of treatment services, many of which focus on sobriety. Sutton said drafters of Measure 110 wanted to avoid anything that might resemble a criminal tribunal or coercing drug users into treatment. “People respond best when they’re ready to access those services in a voluntary way,” he said.
Almost immediately after taking effect, Measure 110 encountered problems. A state audit published this year found that the new law was “vague” about how state officials should oversee the awarding of money to new treatment programs, and set “unrealistic timelines” for evaluating and funding treatment proposals. As a result, the funding process was left largely to the grant-making panel, most of whose members “lacked experience in designing, evaluating and administrating a governmental-grant-application process,” according to the audit. Last year, supporters of Measure 110 accused state health officials, preoccupied with the coronavirus pandemic, of giving the panel insufficient direction and resources to handle a flood of grant applications. The state health authority acknowledged missteps in the grant-making process.
The audit described a chaotic process, with more than a dozen canceled meetings, potential conflicts of interest in the selection of funding recipients, and lines of applicant evaluations left blank. Full distribution of the first biennial payout of cannabis tax revenue—$302 million for harm reduction, housing, and other services—did not occur until late 2022, almost two years after Measure 110 passed. Figures released by the state last month show that, in the second half of 2022, recipients of Measure 110 funding provided some form of service to roughly 50,000 “clients,” though the Oregon Health Authority has said that a single individual could be counted multiple times in that total. (A study released last year by public-health researchers in Oregon found that, as of 2020, more than 650,000 Oregonians required, but were not receiving, treatment for a substance-use disorder.)
Meanwhile, the new law’s enforcement provisions have proved ineffectual. Of 5,299 drug-possession cases filed in Oregon circuit courts since Measure 110 went into effect, 3,381 resulted in a recipient failing to pay the fine or appear in court and facing no further penalties, according to the Oregon Judicial Department; about 1,300 tickets were dismissed or are pending. The state audit found that, during its first 15 months in operation, the treatment-referral hotline received just 119 calls, at a cost to the state of $7,000 per call. A survey of law-enforcement officers conducted by researchers at Portland State University found that, as of July 2022, officers were issuing an average of just 300 drug-possession tickets a month statewide, compared with 600 drug-possession arrests a month before Measure 110 took effect and close to 1,200 monthly arrests prior to the outbreak of COVID-19.
“Focusing on these tickets even though they’ll be ineffective—it’s not a great use of your resources,” Sheriff Nate Sickler of Jackson County, in the rural southern part of the state, told me of his department’s approach.
Advocates have celebrated a plunge in arrests. “For reducing arrests of people of color, it’s been an overwhelming success,” says Mike Marshall, the director of Oregon Recovers. But critics say that sidelining law enforcement has made it harder to persuade some drug users to stop using. Sickler cited the example of drug-court programs, which multiple studies have shown to be highly effective, including in Jackson County. Use of such programs in the county has declined in the absence of criminal prosecution, Sickler said: “Without accountability or the ability to drive a better choice, these individuals are left to their own demise.”
The consequences of Measure 110’s shortcomings have fallen most heavily on Oregon’s drug users. In the two years after the law took effect, the number of annual overdoses in the state rose by 61 percent, compared with a 13 percent increase nationwide, according to the Centers for Disease Control and Prevention. In neighboring Idaho and California, where drug possession remains subject to prosecution, the rate of increase was significantly lower than Oregon’s. (The spike in Washington State was similar to Oregon’s, but that comparison is more complicated because Washington’s drug policy has fluctuated since 2021.) Other states once notorious for drug deaths, including West Virginia, Indiana, and Arkansas, are now experiencing declines in overdose rates.
In downtown Portland this spring, police cleared out what The Oregonian called an “open-air drug market” in a former retail center. Prominent businesses in the area, including the outdoor-gear retailer REI, have closed in recent months, in part citing a rise in shoplifting and violence. Earlier this year, Portland business owners appeared before the Multnomah County Commission to ask for help with crime, drug-dealing, and other problems stemming from a behavioral-health resource center operated by a harm-reduction nonprofit that was awarded more than $4 million in Measure 110 funding. In April, the center abruptly closed following employee complaints that clients were covering walls with graffiti and overdosing on-site. A subsequent investigation by the nonprofit found that a security contractor had been using cocaine on the job. The center reopened two weeks later with beefed-up security measures.
Portland’s Democratic mayor, Ted Wheeler, went so far as to attempt an end run around Measure 110 in his city. Last month, Wheeler unveiled a proposal to criminalize public drug consumption in Portland, similar to existing bans on open-air drinking, saying in a statement that Measure 110 “is not working as it was intended to.” He added, “Portland’s substance-abuse problems have exploded to deadly and disastrous proportions.” Wheeler withdrew the proposal days later after learning that an older state law prohibits local jurisdictions from banning public drug use.
Despite shifting public opinion on Measure 110, many Oregon leaders are not ready to give up on the policy. Earlier this month, Oregon Governor Tina Kotek signed legislation that strengthens state oversight of Measure 110 and requires an audit, due no later than December 2025, of about two dozen aspects of the measure’s performance, including whether it is reducing overdoses. Other bills passed by the legislature’s Democratic majority strengthened criminal penalties for possession of large quantities of fentanyl and mandated that school drug-prevention programs instruct students about the risks of synthetic opioids. Republican proposals to repeal Measure 110 outright or claw back tens of millions of dollars in harm-reduction funding were not enacted.
The fallout from Measure 110 has received some critical coverage from media outlets on the right. “It is predictable,” a scholar from the Hudson Institute told Fox News. “It is a tragedy and a self-inflicted wound.” (Meanwhile, in Portugal, the model for Oregon, some residents are raising questions about their own nation’s decriminalization policy.) But so far Oregon’s experience doesn’t appear to have stopped efforts to bring decriminalization to other parts of the United States. “We’ll see more ballot initiatives,” Sutton, of the Drug Policy Alliance, said, adding that advocates are currently working with city leaders to decriminalize drugs in Washington, D.C.
Supporters of Measure 110 are now seeking to draw attention to what they say are the policy’s overlooked positive effects. This summer, the Health Justice Recovery Alliance, a Measure 110 advocacy organization, is leading an effort to spotlight expanded treatment services and boost community awareness of the treatment-referral hotline. Advocates are also coordinating with law-enforcement agencies to ensure that officers know about local resources for drug users. “People are hiring for their programs; outreach programs are expanding, offering more services,” Devon Downeysmith, the communications director for the group, told me.
An array of services around the state have been expanded through the policy: housing for pregnant women awaiting drug treatment; culturally specific programs for Black, Latino, and Indigenous drug users; and even distribution of bicycle helmets to people unable to drive to treatment meetings. “People often forget how much time it takes to spend a bunch of money and build services,” said Wheelock, the homeless-services worker, whose organization received more than $2 million in funding from Measure 110.
Still, even some recipients of Measure 110 funding wonder whether one of the law’s pillars—the citation system that was supposed to help route drug users into treatment—needs to be rethought. “Perhaps some consequences might be a helpful thing,” says Julia Pinsky, a co-founder of Max’s Mission, a harm-reduction nonprofit in southern Oregon. Max’s Mission has received $1.5 million from Measure 110, enabling the organization to hire new staff, open new offices, and serve more people. Pinsky told me she is proud of her organization’s work and remains committed to the idea that “you shouldn’t have to go to prison to be treated for substance use.” She said that she doesn’t want drug use to “become a felony,” but that some people aren’t capable of stopping drug use on their own. “They need additional help.”
Brandi Fogle, a regional manager for Max’s Mission, says her own story illustrates the complex trade-offs involved in reforming drug policy. Three and a half years ago, she was a homeless drug user, addicted to heroin and drifting around Jackson and Josephine Counties. Although she tried to stop numerous times, including one six-month period during which she was prescribed the drug-replacement medication methadone, she told me that a 2020 arrest for drug possession was what finally turned her life around. She asked to be enrolled in a 19-month drug-court program that included residential treatment, mandatory 12-step meetings, and a community-service project, and ultimately was hired by Pinsky.
Since Measure 110 went into effect, Fogle said, she has gotten pushback from members of the community for the work Max’s Mission does. She said that both the old system of criminal justice and the new system of harm reduction can benefit drug users, but that her hope now is to make the latter approach more successful. “Everyone is different,” Fogle said. “Drug court worked for me because I chose it, and I wouldn’t have needed drug court in the first place if I had received the kind of services Max’s Mission provides. I want to offer people that chance.”
STOCKBRIDGE, Ga., August 21, 2019 (Newswire.com)
– The Fletcher Group has been awarded a $6.6 million grant from the U.S. Department of Health and Human Services (HHS). As part of the Rural Communities Opioid Response Program (RCORP), the grant will support evidence-based efforts to prevent and treat Substance Use Disorders (SUDs) in rural communities.
“We’re extremely honored,” said Fletcher Group Founder Ernie Fletcher. “This grant provides the resources to expand the full spectrum of evidenced-based Recovery Housing, including the highly successful Recovery Kentucky model, across rural America.”
Recovery Kentucky was founded in 2004 by Don Ball and then Kentucky Governor Ernie Fletcher and is well-known for helping thousands of Kentuckians rebuild their lives while saving millions of taxpayer dollars.
Fletcher Group CEO Dave Johnson said the funds will help establish a Recovery Center of Excellence (RCOE) from which technical assistance can be shared with communities and organizations fighting the opioid epidemic.
“The Don Ball Rural Center of Excellence for Recovery Housing,” said Johnson, “will help communities and organizations develop Recovery Housing for high-risk individuals including the homeless and those with SUDs involved in the criminal justice system.”
The Fletcher Group’s RCOE will have a national reach, serving over 100 counties and 2.6 million people in eight states including Kentucky, Georgia, West Virginia, Ohio, Idaho, Montana, Oregon, and Washington.
DENVER, August 9, 2018 (Newswire.com)
– Cordant Health Solutions™, which provides innovative tools for monitoring behavioral health and chronic pain through its unique pharmacy and drug testing programs, is pleased to announce the renewal of its Substance Abuse and Mental Health Services Administration (SAMHSA) certification for its forensic drug testing program that enables Cordant to test specimens for federal agencies.
Cordant has successfully met the strict standards for SAMHSA certification continuously since April 2009 and is currently one of only 27 toxicology companies to hold this certification, one of the most rigorous quality control certification programs in forensic testing.
Quality control programs like SAMHSA and CAP FDT, CAP and CLIA challenge us to maintain the highest level of analytical precision and accuracy and ensure that test results are both accurate and reliable. Our emphasis is always on continuous quality improvement.
Richard Stripp, Ph.D., chief scientific and technical officer
As evidence of the company’s dedication to operational excellence, Cordant is also accredited by the College of American Pathologists for forensic drug testing (CAP FDT), which has stringent requirements for screening and confirmation testing, quality control, and external and internal chain-of-custody procedures which focuses on law enforcement testing.
Cordant is also one of only two toxicology companies outside of California to attain a California license for methadone testing, a medication used in the treatment of opioid use disorder. In addition, Cordant is CAP-accredited and CLIA-certified and is licensed for clinical testing in many states, including New York.
“Quality control programs like SAMHSA and CAP FDT, CAP and CLIA challenge us to maintain the highest level of analytical precision and accuracy and ensure that test results are both accurate and reliable. Our emphasis is always on continuous quality improvement,” said Richard Stripp, Ph.D., chief scientific and technical officer at Cordant. “We view strict internal acceptance criteria as table stakes when it comes to patient results. Test results are not just numbers in a file — they affect lives. We take that responsibility very seriously.”
About Cordant
Based in Denver, Cordant Health Solutions™ (www.cordantsolutions.com) provides innovative tools for monitoring behavioral health, chronic pain and criminal justice cases. Our unique pharmacy and drug testing programs provide accurate, actionable results to protect prescribers, hold patients accountable and optimize quality of life.
As a leader in rigorous quality standards, Cordant is committed to developing groundbreaking solutions for payers, clinicians and organizations involved with substance use disorder, criminal justice and pain management. Cordant is one of the only healthcare companies that offers monitoring and risk assessment tools through its innovative drug testing options and full-service, high-touch pharmacies, which specialize in the complex management and dispensing of controlled substances. Cordant’s testing protocols and digital case-management tools help clients become more efficient and effective in using drug testing programs to monitor patient adherence, reduce risk and improve patient outcomes.
Media Contact: Tiffany Tuetken 303-570-4585 ttuetken@cordanths.com cordantsolutions.com